Edition:
India

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

5.35EUR
3 Aug 2020
Change (% chg)

-- (--)
Prev Close
€5.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
398,099
52-wk High
€5.74
52-wk Low
€1.78

Summary

Name Age Since Current Position

Frederic Grimaud

55 2002 Chairman of the Supervisory Board

Thomas Lingelbach

56 2019 Chairman of the Management Board, President, Chief Executive Officer, Member of the Management Board

Franck Grimaud

52 2019 President & Chief Business Officer and Member of the Executive Committee

Louisa Shaw-Marotto

52 2019 Vice Chairman of the Supervisory Board, Independent Director

David Lawrence

57 2017 Chief Financial Officer, Member of the Management Board

Manfred Tiefenbacher

Vice President - Finance, Member of the Executive Committee

Gerald Strohmaier,

2019 Vice President of Human Resources, Member of the Executive Committee

Jason Golan

Vice President Commercial Operations, Member of the Executive Committee

Olivier Jankowitsch

2017 Vice President Global Supply Operations, Member of the Executive Committee

Andreas Meinke

Vice President Pre-clinical & Translational Research, Member of the Executive Committee

Michael Moehlen

Vice President Corporate Technical Development, Member of the Executive Committee

Klaus Schwamborn

Vice President - Discovery Research & Innovation, Member of the Executive Committee

Frederic Jacotot

56 2019 Member of the Management Board General Counsel & Corporate Secretary

Wolfgang Bender

66 2017 Chief Medical Officer, Member of the Management Board

Janet Hoogstraate

Chair of the Management Board of Valneva Sweden AB, Member of the Executive Committee

Frances Muir

2019 Site Director Livingston, Member of the Executive Committee

Anne-Marie Graffin

58 2013 Independent Member of the Supervisory Board

James Sulat

69 2019 Independent Member of the Supervisory Board

Thomas Casdagli

43 2019 Member of the Supervisory Board - Representative of MVM Partners LLP

Johanna Pattenier

2020 Member of the Supervisory Board

Sharon Tetlow

60 2020 Member of the Supervisory Board

Biographies

Name Description

Frederic Grimaud

Mr. Frederic Grimaud serves as Chairman of the Supervisory Board of the Company. He was Member of the Audit Committee, Strategy and Transactions Committee, and Nominating and Remuneration Committee. He created a company specializing in services for businesses involved in motivational management of human resources and then joined Groupe Grimaud in 1988 to work in the sales division. In the early 1990’s, he participated in the international development of Groupe Grimaud and led biotechnology projects before becoming Chairman of the Management of Board in 2000. Between 2002 and 2015 he served as Chairman of Grimaud Freres Selection SAS and Hypharm SAS, among others. He is currently Chairman of Filavie SAS and Pen Ar Lan SA as well as Member of the Supervisory Board of Genesis Investment, among others.

Thomas Lingelbach

Mr. Thomas Lingelbach serves as Chairman of the Management Board, President, Chief Executive Officer, Member of the Management Board of the Company. He previously served as Chairman of the Management Board and Executive Board, Co-President, Chief Executive Officer of Valneva SE as of 2012. He served at Intercell as of 2006, serving as COO until 2011 and then as its CEO. He joined Intercell from Novartis Vaccine & Diagnostics as Managing Director Germany focusing on the integration with Chiron Vaccine where he served as Vice President Global Industrial Operations and Managing Director Chiron-Behring. Mr. Lingelbach holds a Master's degree in Engineering and complemented his education with a Business Administration program. Currently he is Manager of Gratzelmixer GmbH, Director of Valneva UK and Valneva Canada as well as Chairman of Vaccines Holdings Sweden AB, among others.

Franck Grimaud

Mr. Franck Grimaud serves as President & Chief Business Officer and Member of the Executive Committee of the Company. He was Member of the Management Board, Co-President and Chief Business Officer of Valneva SE (Vivalis SA) as of the Company's merger in 2012. Previously he was the Chairman of the Management Board and the Executive Committee of Vivalis SA from November 29, 2002 to 2012. He holds a Master in Business Administration from Ottawa University, and started his career as an organization and management consultant. He then joined Groupe Grimaud as Head of Development for Asia and then became Head of Development of the Veterinary Vaccines Division before creating Vivalis. He was also appointed Vice Chairman of the Atlantic Biotherapies business cluster and his present and former positions include Chief Executive Officer of Smol Therapeutics SAS, President and Representative Director of Vivalis Toyama Japan KK, and Director of Grimaud Deyang Animal Co Ltd and Chengdu Grimaud Breeding Co Ltd.

Louisa Shaw-Marotto

Ms. Louisa Shaw-Marotto serves as Vice Chairman of the Supervisory Board, Independent Director of the Company. She is Member of company's Audit Committee. She serves as President of Executive Perspective Consulting LLC and Advisory Board Member of Rutgers University and is former Vice President of Marketing at Merck & Co.

David Lawrence

Mr. David Lawrence serves as Chief Financial Officer, Member of the Management Board of the Company. He has over 25 years of experience in the pharmaceutical, biotech and vaccine industries, with a proven international track record in mid-sized to large companies and small biotech start-ups. His tested leadership experience as a CFO in the Lifesciences sector spans across finance and accounting, mergers and acquisitions, fund raising and investor relations. He served as CFO in a dual-listed (LSE and NASDAQ) vaccine biotech company (Acambis plc, acquired by sanofi in 2008) and was Vice President of Finance & Business Development for Chiron Vaccines, a division of Chiron Corporation which was acquired by Novartis in 2005. Prior to these roles, he held senior finance positions at GlaxoSmithKline including Vice President of Financial Management in Research and Development. He is currently also Board Member at Valneva Sweden AB, Vaccines Holdings Sweden and Valneva Canada Inc., among others.

Manfred Tiefenbacher

Gerald Strohmaier,

Jason Golan

Olivier Jankowitsch

Mr. Olivier Jankowitsch is Vice President Global Supply Operations, Member of the Executive Committeeof VALNEVA SE. He was previously responsible for Corporate Development, Manufacturing and Commercial Alliance projects and served as VP Corporate Development and Member of the Executive Committee.

Andreas Meinke

Michael Moehlen

Klaus Schwamborn

Mr. Klaus Schwamborn serves as Vice President - Discovery Research & Innovation, Member of the Executive Committee of the Company. He is responsible for Discovery Research, new technologies and platforms, open Innovation and Collaboration, EB66 support/services.

Frederic Jacotot

Mr. Frederic Jacotot serves as Member of the Management Board General Counsel & Corporate Secretary of the Company. He is responsible for Legal & Business Compliance, IP. He is currently also Board Member at Valneva Sweden AB and Vaccines Holdings Sweden AB as well as Manager of Valneva Austra GmbH.

Wolfgang Bender

Dr. Wolfgang Bender serves as Chief Medical Officer, Member of the Management Board of the Company. He is a global life sciences leader with over 30 years of extensive experience in scientific-medical affairs, R&D and general management of vaccines and pharmaceuticals. He has a broad international profile with an exceptional academic background (MD/PhD, MPH, MHA, DTM&P). He has special competencies in strategy, operational execution and change management, with a record of success working in leadership roles for leading global life sciences companies. He held a variety of senior and international positions in vaccine development and medical affairs, working for leading companies in the field, including Novartis Vaccines and Takeda Vaccines. Prior positions included country manager, corporate strategy and various clinical research roles at major pharmaceutical companies such as Pfizer and the Hoechst Group.

Janet Hoogstraate

Frances Muir

Anne-Marie Graffin

Ms. Anne-Marie Graffin serves as Independent Member of the Supervisory Board of the Company. Ms. Graffin is Member of company's Nominating and Remuneration Committee. She serves as Member of the Supervisory Board at NANOBIOTIX S.A., Non-Executive Independent Director at SARTORIUS STEDIM BIOTECH S.A. and Manager of SARL SMAG Consulting. She holds degree from ESSEC Business School.

James Sulat

Mr. James (Jim) R. Sulat serves as Independent Member of the Supervisory Board of the Company. He is Chairman of company's Audit Committee. He served as CFO for Chiron and CEO of Maxygen. Currently he holds various posts including Board Member at Momenta Pharmaceuricals, AMAG Pharmaceuticals Inc and Arch Therapeutics Inc.

Thomas Casdagli

Mr. Thomas T. Casdagli serves as Member of the Supervisory Board - Representative of MVM Partners LLP of the Company. He joined MVM Partners in 2002 and has 17 years experience in investing in innovative life science companies. Before joining MVM, he qualified as a chartered accountant with PricewaterhouseCoopers' Private Equity and Venture Capital practice. Thomas Casdagli has an MBioch in Molecular and Cellular Biochemistry from Oxford University and is currently a member of the boards of eZono AG, Onbone Oy and Patient Connect Ltd.

Johanna Pattenier

Ms. Johanna Willemina Pattenier serves as Member of the Supervisory Board of the Company. he spent most of her career in vaccines leadership roles across commercial, clinical development, medical, market access functions as well as general management. Dr.Pattenier successfully led late stage development and market access programs for new vaccines, including HPV and Meningitis B. Most recently, she served as General Manager of Novartis Vaccines and Diagnostics (now a GlaxoSmithKline (GSK) company) in Basel and GSK / Novartis vaccines integration lead. Prior to that, Dr. Pattenier’s international career included commercial and medical roles at GSK, Organon and Byk Gulden.

Sharon Tetlow

Ms. Sharon Elizabeth Tetlow serves as Member of the Supervisory Board of the Company. Ms. Tetlow founded and serves as Managing Partner of Potrero Hill Advisors (PHA). In her role at PHA and through her career as a serial CFO, she has lead and executed successful financial strategies. Prior to PHA,  Ms. Tetlow was managing director of Danforth Advisors, a similar financial advisory firm and held previous CFO/senior finance roles at Cell Genesys, Pathwork Dx, diaDexus, among others. She currently serves as Audit Committee Chair on the Board of Directors of Catalyst Biosciences (NASDAQ:CBIO) and on the board of Katherine Michiels School Project Open Mind, an education-related not-for-profit in San Francisco. Ms. Tetlow earned a B.A. from the University of Delaware and M.B.A. from Stanford University.